Mesenchymal stem cells (MSCs) are a key tool in regenerative medicine because of their ability to differentiate into various tissues, modulate the immune system and promote cellular repair. Derived from tissues such as bone marrow, adipose tissue or umbilical cord, they are divided into autologous (from the patient) and allogeneic (from a donor). Both have advantages and challenges, but the regulation of allogeneic MSCs is crucial to ensure patient safety, especially in Argentina, where their use is not fully regulated.
Mesenchymal Stem Cells: Autologous vs. Allogeneic MSCs
Autologous MSCs are obtained from the patient, eliminating the risk of immunologic rejection. However, their availability may be limited by the physician’s operability and experience in obtaining them. It is crucial to count on a team of referents, as is the case in Stem Cell Therapy Argentina, which provides 100% autologous treatments, that is to say, with the patient’s own cells.
Allogeneic MSCs, on the other hand, come from healthy donors, their sources are from the cord, they are available under a very expensive production and maintenance process. However, they involve risks of immunological reactions and require strict quality controls where they must be certified prior to placement.
The Lack of Regulation of Allogeneic MSCs in Argentina
In Argentina, allogeneic MSCs, particularly imported ones, operate in an insufficient regulatory framework. While autologous MSCs have certain controls since it is a product obtained from the patient himself and re-injected at the same time, allogeneic MSCs are often imported and applied without the authorization of the corresponding Customs. This practice exposes patients to significant risks, such as contaminated cells, of poor quality or without proven efficacy.
There are patients who have reported having been treated in Argentina, by doctors where they have obtained these cells, they do not know their origin and they are applied in the doctor’s office.
This can lead to risks related to:
– Infections: From microbial or viral contamination during collection, processing or transport.
– Immunological reactions: Due to incompatibilities between donor and recipient cells.
– Ineffectiveness: Poor quality or poorly stored cells that do not produce the expected therapeutic effect.
– Lack of traceability: Unknown origin of the cells, which makes it difficult to guarantee their safety and ethics.
The importance of a medical product entering legally.
Legal authorization of a drug is essential to ensure that imported allogeneic MSCs are safe and effective. This body ensures:
Quality: Production in certified laboratories, minimizing contamination risks.
Safety: Tests to rule out communicable diseases or adverse reactions.
Without these controls, patients are at risk of serious complications, such as infections or ineffective treatments.
Professional Responsibility and Patient Protection
It is worrying that some professionals import or manage to bring in these products and apply allogeneic MSCs without complying with the regulations of a drug, putting patients at risk and discrediting regenerative medicine. Professionals should:
- Comply with regulations: Obtain legal and customs clearance for imported products.
- Inform the patient: Explain risks and benefits, stressing the importance of regulated products.
- Science-based: Use treatments with solid clinical evidence.
Avoiding Risks in Cord Blood Cell Treatments
The use of umbilical cord cells without quality controls is of particular concern. These cells, if not properly processed, stored or transported, lose their viability and may become useless or dangerous. Some specific risks include:
– Improper storage: Cord cells require cryopreservation at specific temperatures. Poor handling can damage them. The same happens with X-rays if they are transported by simple means in non-corresponding luggage.
– Lack of certification: Unregulated cord banks may provide cells without quality or safety testing.
– Uncontrolled importation: Cells from international banks without ANMAT authorization may not comply with sanitary standards.
To avoid these risks, patients should make sure that the cord cells come from certified banks and that their use is authorized as an imported drug, since it is considered an advanced therapy drug. In addition, it is crucial that professionals report on the origin and quality of the cells used.
Professional Responsibility and Patient Protection
The practice of importing and applying allogeneic MSCs or cord cells without authorization is alarming. These actions not only jeopardize the health of patients, but also affect the credibility of regenerative medicine. Practitioners have an ethical and legal responsibility to:
– Comply with regulations: Obtain authorization for any imported product.
– Quality assurance: Use cells from certified sources and with rigorous controls.
– Inform the patient: Explain risks and benefits, stressing the importance of regulated products.
– Evidence-based: Apply treatments supported by clinical studies, avoiding exaggerated promises.
Conclusion: For a Safe Use of Allogeneic MSCs
Autologous and allogeneic MSCs offer enormous potential for treating diseases such as osteoarthritis or neurological injuries. However, their use requires strict regulation.
Let us demand transparency and accountability in these therapies. Patients deserve safe, science-based treatments. Only with a regulated and ethical approach can we harness the power of mesenchymal stem cells.
Call to action: If you are looking for stem cell treatment, verify that the products are authorized, demand quality controls such as temperature reports, microbiological controls and flow cytometry controls. And consult with certified and authorized professionals. Your health comes first.
